

RNAi for Therapeutic-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/RB5BCD74B8EEN.html>

Date: December 2021

Pages: 131

Price: US\$ 3,680.00 (Single User License)

ID: RB5BCD74B8EEN

Abstracts

Report Summary

RNAi for Therapeutic-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on RNAi for Therapeutic industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of RNAi for Therapeutic 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of RNAi for Therapeutic worldwide and market share by regions, with company and product introduction, position in the RNAi for Therapeutic market

Market status and development trend of RNAi for Therapeutic by types and applications
Cost and profit status of RNAi for Therapeutic, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium RNAi for Therapeutic market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive

slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the RNAi for Therapeutic industry.

The report segments the global RNAi for Therapeutic market as:

Global RNAi for Therapeutic Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global RNAi for Therapeutic Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):

siRNA

miRNA

shRNA

Global RNAi for Therapeutic Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Global RNAi for Therapeutic Market: Manufacturers Segment Analysis (Company and Product introduction, RNAi for Therapeutic Sales Volume, Revenue, Price and Gross Margin):

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF RNAI FOR THERAPEUTIC

- 1.1 Definition of RNAi for Therapeutic in This Report
- 1.2 Commercial Types of RNAi for Therapeutic
 - 1.2.1 siRNA
 - 1.2.2 miRNA
 - 1.2.3 shRNA
- 1.3 Downstream Application of RNAi for Therapeutic
 - 1.3.1 Alnylam Pharmaceuticals
 - 1.3.2 Arbutus Biopharma (Tekmira)
 - 1.3.3 Arrowhead
 - 1.3.4 Dicerna Pharmaceuticals
- 1.4 Development History of RNAi for Therapeutic
- 1.5 Market Status and Trend of RNAi for Therapeutic 2016-2026
 - 1.5.1 Global RNAi for Therapeutic Market Status and Trend 2016-2026
 - 1.5.2 Regional RNAi for Therapeutic Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of RNAi for Therapeutic 2016-2021
- 2.2 Sales Market of RNAi for Therapeutic by Regions
 - 2.2.1 Sales Volume of RNAi for Therapeutic by Regions
 - 2.2.2 Sales Value of RNAi for Therapeutic by Regions
- 2.3 Production Market of RNAi for Therapeutic by Regions
- 2.4 Global Market Forecast of RNAi for Therapeutic 2022-2026
 - 2.4.1 Global Market Forecast of RNAi for Therapeutic 2022-2026
 - 2.4.2 Market Forecast of RNAi for Therapeutic by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of RNAi for Therapeutic by Types
- 3.2 Sales Value of RNAi for Therapeutic by Types
- 3.3 Market Forecast of RNAi for Therapeutic by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of RNAi for Therapeutic by Downstream Industry
- 4.2 Global Market Forecast of RNAi for Therapeutic by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America RNAi for Therapeutic Market Status by Countries
 - 5.1.1 North America RNAi for Therapeutic Sales by Countries (2016-2021)
 - 5.1.2 North America RNAi for Therapeutic Revenue by Countries (2016-2021)
 - 5.1.3 United States RNAi for Therapeutic Market Status (2016-2021)
 - 5.1.4 Canada RNAi for Therapeutic Market Status (2016-2021)
 - 5.1.5 Mexico RNAi for Therapeutic Market Status (2016-2021)
- 5.2 North America RNAi for Therapeutic Market Status by Manufacturers
- 5.3 North America RNAi for Therapeutic Market Status by Type (2016-2021)
 - 5.3.1 North America RNAi for Therapeutic Sales by Type (2016-2021)
 - 5.3.2 North America RNAi for Therapeutic Revenue by Type (2016-2021)
- 5.4 North America RNAi for Therapeutic Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe RNAi for Therapeutic Market Status by Countries
 - 6.1.1 Europe RNAi for Therapeutic Sales by Countries (2016-2021)
 - 6.1.2 Europe RNAi for Therapeutic Revenue by Countries (2016-2021)
 - 6.1.3 Germany RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.4 UK RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.5 France RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.6 Italy RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.7 Russia RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.8 Spain RNAi for Therapeutic Market Status (2016-2021)
 - 6.1.9 Benelux RNAi for Therapeutic Market Status (2016-2021)
- 6.2 Europe RNAi for Therapeutic Market Status by Manufacturers
- 6.3 Europe RNAi for Therapeutic Market Status by Type (2016-2021)
 - 6.3.1 Europe RNAi for Therapeutic Sales by Type (2016-2021)
 - 6.3.2 Europe RNAi for Therapeutic Revenue by Type (2016-2021)
- 6.4 Europe RNAi for Therapeutic Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,

MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific RNAi for Therapeutic Market Status by Countries
 - 7.1.1 Asia Pacific RNAi for Therapeutic Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific RNAi for Therapeutic Revenue by Countries (2016-2021)
 - 7.1.3 China RNAi for Therapeutic Market Status (2016-2021)
 - 7.1.4 Japan RNAi for Therapeutic Market Status (2016-2021)
 - 7.1.5 India RNAi for Therapeutic Market Status (2016-2021)
 - 7.1.6 Southeast Asia RNAi for Therapeutic Market Status (2016-2021)
 - 7.1.7 Australia RNAi for Therapeutic Market Status (2016-2021)
- 7.2 Asia Pacific RNAi for Therapeutic Market Status by Manufacturers
- 7.3 Asia Pacific RNAi for Therapeutic Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific RNAi for Therapeutic Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific RNAi for Therapeutic Revenue by Type (2016-2021)
- 7.4 Asia Pacific RNAi for Therapeutic Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America RNAi for Therapeutic Market Status by Countries
 - 8.1.1 Latin America RNAi for Therapeutic Sales by Countries (2016-2021)
 - 8.1.2 Latin America RNAi for Therapeutic Revenue by Countries (2016-2021)
 - 8.1.3 Brazil RNAi for Therapeutic Market Status (2016-2021)
 - 8.1.4 Argentina RNAi for Therapeutic Market Status (2016-2021)
 - 8.1.5 Colombia RNAi for Therapeutic Market Status (2016-2021)
- 8.2 Latin America RNAi for Therapeutic Market Status by Manufacturers
- 8.3 Latin America RNAi for Therapeutic Market Status by Type (2016-2021)
 - 8.3.1 Latin America RNAi for Therapeutic Sales by Type (2016-2021)
 - 8.3.2 Latin America RNAi for Therapeutic Revenue by Type (2016-2021)
- 8.4 Latin America RNAi for Therapeutic Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa RNAi for Therapeutic Market Status by Countries
 - 9.1.1 Middle East and Africa RNAi for Therapeutic Sales by Countries (2016-2021)
 - 9.1.2 Middle East and Africa RNAi for Therapeutic Revenue by Countries (2016-2021)

- 9.1.3 Middle East RNAi for Therapeutic Market Status (2016-2021)
- 9.1.4 Africa RNAi for Therapeutic Market Status (2016-2021)
- 9.2 Middle East and Africa RNAi for Therapeutic Market Status by Manufacturers
- 9.3 Middle East and Africa RNAi for Therapeutic Market Status by Type (2016-2021)
 - 9.3.1 Middle East and Africa RNAi for Therapeutic Sales by Type (2016-2021)
 - 9.3.2 Middle East and Africa RNAi for Therapeutic Revenue by Type (2016-2021)
- 9.4 Middle East and Africa RNAi for Therapeutic Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF RNAI FOR THERAPEUTIC

- 10.1 Global Economy Situation and Trend Overview
- 10.2 RNAi for Therapeutic Downstream Industry Situation and Trend Overview

CHAPTER 11 RNAI FOR THERAPEUTIC MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of RNAi for Therapeutic by Major Manufacturers
- 11.2 Production Value of RNAi for Therapeutic by Major Manufacturers
- 11.3 Basic Information of RNAi for Therapeutic by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of RNAi for Therapeutic Major Manufacturer
 - 11.3.2 Employees and Revenue Level of RNAi for Therapeutic Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 RNAI FOR THERAPEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Alnylam Pharmaceuticals
 - 12.1.1 Company profile
 - 12.1.2 Representative RNAi for Therapeutic Product
 - 12.1.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
- 12.2 Arbutus Biopharma (Tekmira)
 - 12.2.1 Company profile

- 12.2.2 Representative RNAi for Therapeutic Product
- 12.2.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arbutus Biopharma (Tekmira)
- 12.3 Arrowhead
 - 12.3.1 Company profile
 - 12.3.2 Representative RNAi for Therapeutic Product
 - 12.3.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arrowhead
- 12.4 Dicerna Pharmaceuticals
 - 12.4.1 Company profile
 - 12.4.2 Representative RNAi for Therapeutic Product
 - 12.4.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals
- 12.5 Mirna Therapeutics
 - 12.5.1 Company profile
 - 12.5.2 Representative RNAi for Therapeutic Product
 - 12.5.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Mirna Therapeutics
- 12.6 Quark Pharmaceuticals
 - 12.6.1 Company profile
 - 12.6.2 Representative RNAi for Therapeutic Product
 - 12.6.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals
- 12.7 RXi Pharmaceuticals
 - 12.7.1 Company profile
 - 12.7.2 Representative RNAi for Therapeutic Product
 - 12.7.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of RXi Pharmaceuticals
- 12.8 Silence Therapeutics
 - 12.8.1 Company profile
 - 12.8.2 Representative RNAi for Therapeutic Product
 - 12.8.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silence Therapeutics
- 12.9 Benitec Biopharma
 - 12.9.1 Company profile
 - 12.9.2 Representative RNAi for Therapeutic Product
 - 12.9.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Benitec Biopharma
- 12.10 miRagen Therapeutics
 - 12.10.1 Company profile

- 12.10.2 Representative RNAi for Therapeutic Product
- 12.10.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of miRagen Therapeutics
- 12.11 Sylentis
 - 12.11.1 Company profile
 - 12.11.2 Representative RNAi for Therapeutic Product
 - 12.11.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sylentis
- 12.12 Gradalis
 - 12.12.1 Company profile
 - 12.12.2 Representative RNAi for Therapeutic Product
 - 12.12.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Gradalis
- 12.13 Sirnaomics
 - 12.13.1 Company profile
 - 12.13.2 Representative RNAi for Therapeutic Product
 - 12.13.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sirnaomics
- 12.14 Silenseed
 - 12.14.1 Company profile
 - 12.14.2 Representative RNAi for Therapeutic Product
 - 12.14.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silenseed

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RNAI FOR THERAPEUTIC

- 13.1 Industry Chain of RNAi for Therapeutic
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF RNAI FOR THERAPEUTIC

- 14.1 Cost Structure Analysis of RNAi for Therapeutic
- 14.2 Raw Materials Cost Analysis of RNAi for Therapeutic
- 14.3 Labor Cost Analysis of RNAi for Therapeutic
- 14.4 Manufacturing Expenses Analysis of RNAi for Therapeutic

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: RNAi for Therapeutic-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/RB5BCD74B8EEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RB5BCD74B8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

